Clinical trials: Diabetes, Type 2
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.
- Trial name
- NCT01507311
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01965509
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy…
- Trial name
- NCT06829563
- Testing
- RZ-629, Fasted, Fed
- Where
- Australia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Rezubio Pharmaceuticals Co., Ltd.
Healthy Volunteers, Hepatic Insufficiency
A Single Dose Study of LY2605541 in Participants With Liver Impairment
The primary purpose of this study is to help answer the following research questions: To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those…
- Conditions
- Healthy Volunteers, Hepatic Insufficiency, Diabetes Mellitus, Type 2
- Trial name
- NCT01751399
- Testing
- LY2605541
- Where
- 2 sites in Germany, Hungary
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human (FIH) study to evaluate the safety, tolerability, food effect (FE), pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered XW014 in…
- Trial name
- NCT05579314
- Testing
- XW014
- Where
- 3 sites in United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes
MagDI Canada Study
The objective of the MagDI Canada study is to evaluate the performance and safety of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial…
- Trial name
- NCT06467955
- Testing
- Magnet System, DI Biofragmentable
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- GT Metabolic Solutions, Inc.
Diabetes Mellitus, Type 2
A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents
The purpose of this study is to evaluate the safety and glycemic control of SHR-3167 fixed-dose titration and individualized-dose titration in adults with Type 2 Diabetes inadequately controlled with oral antihyperglycemic agents.
- Trial name
- NCT07472725
- Testing
- SHR-3167 Injection
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 2
An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients
The purpose of this study is to demonstrate that the rosiglitazone/glimepiride fixed-dose combination tablet will safely and effectively control glycemia as first-line oral therapy in drug naïve subjects with type 2 diabetes.
- Trial name
- NCT01453049
- Testing
- rosiglitazone/glimepiride fix dose combination, glimepiride
- Where
- 12 sites in China
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. This is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, in…
- Trial name
- NCT00138606
- Testing
- vildagliptin
- Where
- 2 sites in United States, Germany
- Volunteers
- 179 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus (T2DM)
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
The main purpose of this study is to investigate the Efficacy and Safety of GZR18 Injection in Chinese Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
- Trial name
- Optimum 1 (NCT06777238)
- Testing
- GZR18
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Type 2 Diabetes Mellitus
Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
The study objective is to demonstrate the superiority and safety of the combination therapy (as a fix-dose combination) with Gemigliptin and Glimepiride, compared to the Glimepiride monotherapy in patients with type 2 diabetes.
- Trial name
- NCT02089126
- Testing
- Gemigliptin/Glimepiride combination
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Multiple Electrode Aggregometry & Clopidogrel Resistance
Antiplatelet therapy with aspirin-clopidogrel reduces the risk of cardiovascular episodes after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD), Myocardial Infraction
- Trial name
- NCT01991093
- Where
- 3 sites in Greece
- Volunteers
- 280 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Type2 Diabetes
The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes
The purpose of this study is to prove that the group treated with CKD-501 in combination added that the reduction of glycated hemoglobin superior to placebo treated group added in combination.
- Trial name
- NCT03641352
- Testing
- CKD-501 0.5mg
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose…
- Trial name
- NCT06290349
- Testing
- DA5221-T1, DA5221-T2, DA5221-B1
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes Mellitus
A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.
- Trial name
- NCT03736785
- Testing
- LY3209590, Insulin Degludec
- Where
- 44 sites in United States, Mexico and 1 more
- Volunteers
- 399 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
The purpose of this study is to assess safety and efficacy of empagliflozin compared to sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on treatment with metformin and have insufficient glycaemic…
- Trial name
- NCT01984606
- Testing
- Empagliflozin, Sitagliptin
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with…
- Trial name
- NCT00622284
- Testing
- BI 1356, Glimepiride
- Where
- 221 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,560 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.
- Trial name
- NCT00701935
- Testing
- exenatide
- Where
- 17 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Japan. The purpose is to compare the safety of once-weekly dosing of semaglutide (0.5 and 1.0 mg) versus sitagliptin (100 mg) once daily, both as monotherapy during 30 weeks of treatment in Japanese…
- Trial name
- SUSTAIN™ (NCT02254291)
- Testing
- semaglutide, sitagliptin
- Where
- 25 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.